MA55811A - Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associés - Google Patents
Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associésInfo
- Publication number
- MA55811A MA55811A MA055811A MA55811A MA55811A MA 55811 A MA55811 A MA 55811A MA 055811 A MA055811 A MA 055811A MA 55811 A MA55811 A MA 55811A MA 55811 A MA55811 A MA 55811A
- Authority
- MA
- Morocco
- Prior art keywords
- tgfbr2
- locus
- modified
- methods
- cells expressing
- Prior art date
Links
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 title 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 title 1
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46443—Growth factors
- A61K39/464434—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962841575P | 2019-05-01 | 2019-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA55811A true MA55811A (fr) | 2022-03-09 |
Family
ID=70918970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA055811A MA55811A (fr) | 2019-05-01 | 2020-04-30 | Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associés |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220184131A1 (fr) |
EP (1) | EP3962520A1 (fr) |
JP (1) | JP2022531222A (fr) |
KR (1) | KR20220016475A (fr) |
CN (1) | CN114025788A (fr) |
AU (1) | AU2020265741A1 (fr) |
BR (1) | BR112021021075A2 (fr) |
CA (1) | CA3136737A1 (fr) |
IL (1) | IL287207A (fr) |
MA (1) | MA55811A (fr) |
MX (1) | MX2021013219A (fr) |
SG (1) | SG11202111360YA (fr) |
WO (1) | WO2020223535A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2024515037A (ja) * | 2021-03-30 | 2024-04-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 改変Fc受容体による移植細胞保護 |
WO2022232277A1 (fr) * | 2021-04-27 | 2022-11-03 | TCR2 Therapeutics Inc. | COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS DE REPROGRAMMATION TCR À L'AIDE DE PROTÉINES DE FUSION ET DE COMMUTATION TGFβR |
WO2022232840A1 (fr) * | 2021-04-29 | 2022-11-03 | The Regents Of The University Of California | Systèmes et procédés d'édition génétique avec une efficacité accrue |
WO2022266139A2 (fr) * | 2021-06-14 | 2022-12-22 | Graphite Bio, Inc. | Procédés de modification génétique de cellules souches et progénitrices hématopoïétiques pour l'expression spécifique d'érythrocytes de protéines thérapeutiques |
EP4376873A1 (fr) * | 2021-07-26 | 2024-06-05 | CRISPR Therapeutics AG | Procédés de fabrication de cellules car-t génétiquement modifiées |
WO2023010436A1 (fr) * | 2021-08-05 | 2023-02-09 | 卡瑞济(北京)生命科技有限公司 | Construction d'expression de tcr, son procédé de préparation et son utilisation |
WO2023072081A1 (fr) * | 2021-10-25 | 2023-05-04 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Animal non humain génétiquement modifié comportant un tgfbr2 humain ou chimérique |
WO2023081900A1 (fr) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Lymphocytes t modifiés exprimant un récepteur recombiné de lymphocytes t (tcr) et systèmes et procédés apparentés |
CA3237754A1 (fr) * | 2021-11-15 | 2023-05-19 | Neogene Therapeutics B.V. | Lymphocytes t modifies ayant une signalisation de recepteur tgf-beta reduite |
WO2023111913A1 (fr) * | 2021-12-15 | 2023-06-22 | Crispr Therapeutics Ag | Cellule anti-liv1 modifiée avec lyse de régnase-1 et/ou tgfbrii |
US20230303713A1 (en) * | 2022-03-23 | 2023-09-28 | Crispr Therapeutics Ag | Anti-cd19 car-t cells with multiple gene edits and therapeutic uses thereof |
WO2024058589A1 (fr) * | 2022-09-16 | 2024-03-21 | 한국과학기술연구원 | Cellule de récepteur antigénique chimérique préparée à l'aide d'une technique de knock-in par ciseaux génétiques et son utilisation |
WO2024102860A1 (fr) * | 2022-11-09 | 2024-05-16 | Shoreline Biosciences, Inc. | Cellules ingéniérisées pour une thérapie |
Family Cites Families (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
IN165717B (fr) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
ES2067018T3 (es) | 1988-12-28 | 1995-03-16 | Stefan Miltenyi | Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos. |
US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
AU650085B2 (en) | 1990-11-13 | 1994-06-09 | Immunex Corporation | Bifunctional selectable fusion genes |
DE4123760C2 (de) | 1991-07-18 | 2000-01-20 | Dade Behring Marburg Gmbh | Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2 |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
DE4228458A1 (de) | 1992-08-27 | 1994-06-01 | Beiersdorf Ag | Multicistronische Expressionseinheiten und deren Verwendung |
WO1994028143A1 (fr) | 1993-05-21 | 1994-12-08 | Targeted Genetics Corporation | Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd) |
CA2681922C (fr) | 1994-01-18 | 2012-05-15 | The Scripps Research Institute | Derives de proteine a doigts zinciques et procedes associes |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
JP4118327B2 (ja) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Dna認識のための結合タンパク質におけるまたはそれに関連する改良 |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
WO1996013593A2 (fr) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Recepteurs de lymphocites t monocatenaires solubles |
WO1996018105A1 (fr) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Recepteur de lymphocyte t monocatenaire |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5840306A (en) | 1995-03-22 | 1998-11-24 | Merck & Co., Inc. | DNA encoding human papillomavirus type 18 |
US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
WO1997034634A1 (fr) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
JP2001519143A (ja) | 1997-10-02 | 2001-10-23 | スノル・モレキュラー・コーポレーション | 可溶性の一本鎖t細胞レセプタータンパク質 |
NZ507887A (en) | 1998-05-19 | 2002-12-20 | Avidex Ltd | Soluble T cell receptor |
EP1109921A4 (fr) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
WO2000023573A2 (fr) | 1998-10-20 | 2000-04-27 | City Of Hope | Cellules modifiees specifiques a la molecule cd20 et utilisation de ces dernieres pour l'immunotherapie cellulaires des malignites cd20?+¿ |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6503717B2 (en) | 1999-12-06 | 2003-01-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6689558B2 (en) | 2000-02-08 | 2004-02-10 | Sangamo Biosciences, Inc. | Cells for drug discovery |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
US20030044787A1 (en) | 2000-05-16 | 2003-03-06 | Joung J. Keith | Methods and compositions for interaction trap assays |
EP1287357A2 (fr) | 2000-06-02 | 2003-03-05 | Memorial Sloan-Kettering Cancer Center | Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
CA2425862C (fr) | 2000-11-07 | 2013-01-22 | City Of Hope | Cellules immunitaires specifiques a cd19 redirigees |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
ATE290020T1 (de) | 2001-08-31 | 2005-03-15 | Avidex Ltd | Löslicher t zell rezeptor |
US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
BRPI0307383B1 (pt) | 2002-01-23 | 2019-12-31 | The Univ Of Utah Research Foundation | método de recombinação genética direcionada em célula de planta hospedeira |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
EP1485075A4 (fr) | 2002-02-20 | 2006-04-26 | Dyax Corp | Ligands de liaison au complexe mhc-peptide |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
WO2003080809A2 (fr) | 2002-03-21 | 2003-10-02 | Sangamo Biosciences, Inc. | Procedes et compositions permettant d'utiliser des endonucleases a doigts de zinc pour ameliorer la recombinaison homologue |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
WO2004037977A2 (fr) | 2002-09-05 | 2004-05-06 | California Institute Of Thechnology | Utilisation de nucleases chimeres pour stimuler le ciblage de genes |
US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
SI2511297T1 (sl) | 2004-02-06 | 2015-07-31 | Morphosys Ag | Proti -CD38 humana protitelesa in njihova uporaba |
US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20060034850A1 (en) | 2004-05-27 | 2006-02-16 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
US20090304679A1 (en) | 2004-05-27 | 2009-12-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
DK1791865T3 (da) | 2004-06-29 | 2010-11-01 | Immunocore Ltd | Celler der udtrykker en modificeret T-cellerecptor |
US20080131962A1 (en) | 2006-05-25 | 2008-06-05 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
WO2006033859A2 (fr) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Production de proteines: compositions et methodes |
MX2007003910A (es) | 2004-10-01 | 2007-06-07 | Avidex Ltd | Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos. |
CN112480257A (zh) | 2005-03-23 | 2021-03-12 | 根马布股份公司 | 用于治疗多发性骨髓瘤的cd38抗体 |
AU2007267874B2 (en) | 2006-05-25 | 2012-03-15 | Sangamo Therapeutics, Inc. | Methods and compositions for gene inactivation |
EP1914242A1 (fr) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Nouveau anticorps Anti-CD38 pour le traitement du cancer |
US8361473B2 (en) | 2007-03-29 | 2013-01-29 | Technion Research & Development Foundation Ltd. | Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases |
EP3357338A1 (fr) | 2007-03-30 | 2018-08-08 | Memorial Sloan-Kettering Cancer Center | Expression constitutive de ligands costimulants sur des lymphocytes t transférés de manière adoptive |
ATE489465T1 (de) | 2007-04-26 | 2010-12-15 | Sangamo Biosciences Inc | Gezielte integration in die ppp1r12c-position |
NO2227271T3 (fr) | 2007-12-07 | 2018-06-23 | ||
US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
JP5990365B2 (ja) | 2007-12-26 | 2016-09-14 | バイオテスト・アクチエンゲゼルシヤフト | Cd138を標的とする剤及びその使用 |
WO2009131632A1 (fr) | 2008-04-14 | 2009-10-29 | Sangamo Biosciences, Inc. | Constructions donneuses linéaires pour une intégration ciblée |
US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
CN102159722B (zh) | 2008-08-22 | 2014-09-03 | 桑格摩生物科学股份有限公司 | 用于靶向单链切割和靶向整合的方法和组合物 |
US8603477B2 (en) | 2008-10-31 | 2013-12-10 | Abbvie Biotherapeutics Inc. | Use of anti-CS1 antibodies for treatment of rare lymphomas |
ES2627552T3 (es) | 2008-12-04 | 2017-07-28 | Sigma Aldrich Company | Edición de genoma en ratas usando nucleasas con dedos de cinc |
US8466260B2 (en) | 2009-04-01 | 2013-06-18 | Genentech, Inc. | Anti-FcRH5 antibodies and immunoconjugates and methods of use |
US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
CA2779526C (fr) | 2009-11-03 | 2022-12-06 | City Of Hope | Recepteur du facteur de croissance de l'epiderme tronque (egfrt) pour la selection de lymphocytes t transduits |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
SG177025A1 (en) | 2010-06-21 | 2012-01-30 | Agency Science Tech & Res | Hepatitis b virus specific antibody and uses thereof |
WO2011100058A1 (fr) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Modification génomique ciblée avec des molécules donneuses partiellement monocaténaires |
CA2796600C (fr) | 2010-04-26 | 2019-08-13 | Sangamo Biosciences, Inc. | Edition du genome d'un locus de rosa en utilisant des nucleases a doigt de zinc |
EP2596011B1 (fr) | 2010-07-21 | 2018-10-03 | Sangamo Therapeutics, Inc. | Méthodes et compositions pour modifier un locus hla |
CA2818992C (fr) | 2010-12-01 | 2021-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticorps ror1 chimeriques lapin/humain |
BR122021026169B1 (pt) | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | Uso de uma célula |
CA3102782A1 (fr) | 2010-12-14 | 2012-06-21 | University Of Maryland, Baltimore | Lymphocytes t exprimant un recepteur d'antigene chimerique anti-etiquette universel et methodes de traitement du cancer |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
AU2012230780B2 (en) | 2011-03-23 | 2016-10-27 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
AU2012236068A1 (en) | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
KR101982360B1 (ko) | 2011-04-05 | 2019-05-24 | 셀렉티스 | 콤팩트 tale-뉴클레아제의 발생 방법 및 이의 용도 |
US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
CA2848417C (fr) | 2011-09-21 | 2023-05-02 | Sangamo Biosciences, Inc. | Procedes et compositions de regulation de l'expression d'un transgene |
AU2012328682B2 (en) | 2011-10-27 | 2017-09-21 | Sangamo Therapeutics, Inc. | Methods and compositions for modification of the HPRT locus |
KR102134932B1 (ko) | 2011-11-11 | 2020-07-17 | 프레드 헛친슨 켄서 리서치 센터 | 암을 위한 사이클린 a1―표적화된 t―세포 면역요법 |
WO2013074999A1 (fr) | 2011-11-16 | 2013-05-23 | Sangamo Biosciences, Inc. | Protéines de liaison d'adn modifiées et utilisations de celles-ci |
EP2814846B1 (fr) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci |
WO2013126726A1 (fr) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation |
CN104395462B (zh) | 2012-05-03 | 2017-09-26 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
AU2013259647B2 (en) | 2012-05-07 | 2018-11-08 | Corteva Agriscience Llc | Methods and compositions for nuclease-mediated targeted integration of transgenes |
RS61345B1 (sr) | 2012-08-20 | 2021-02-26 | Hutchinson Fred Cancer Res | Postupak i kompozicije za ćelijsku imunoterapiju |
ES2743738T3 (es) | 2012-10-02 | 2020-02-20 | Memorial Sloan Kettering Cancer Center | Composiciones y métodos para inmunoterapia |
EP3763810A3 (fr) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | Composés de modification de cellules t et leurs utilisations |
WO2014089212A1 (fr) | 2012-12-05 | 2014-06-12 | Sangamo Biosciences, Inc. | Procédés et compositions pour la régulation de troubles métaboliques |
JP5372297B1 (ja) | 2012-12-20 | 2013-12-18 | 三菱電機株式会社 | 車載装置及びプログラム |
CA2901115A1 (fr) | 2013-02-15 | 2014-08-21 | The Regents Of The University Of California | Recepteur antigenique chimerique heterodimere conditionnellement actif et procede d'utilisation |
WO2014151960A2 (fr) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Procédés de régulation de la prolifération cellulaire |
CN116083487A (zh) | 2013-05-15 | 2023-05-09 | 桑格摩生物治疗股份有限公司 | 用于治疗遗传病状的方法和组合物 |
WO2014191128A1 (fr) | 2013-05-29 | 2014-12-04 | Cellectis | Procédé de manipulation de cellules t pour l'immunothérapie au moyen d'un système de nucléase cas guidé par l'arn |
AR096687A1 (es) | 2013-06-24 | 2016-01-27 | Genentech Inc | Anticuerpos anti-fcrh5 |
US9822162B2 (en) | 2013-07-15 | 2017-11-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human papillomavirus 16 E6 T cell receptors |
EP4137564A1 (fr) | 2013-07-15 | 2023-02-22 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Procédés de préparation de lymphocytes t anti-antigène du papillomavirus humain |
DK3027204T3 (da) | 2013-07-29 | 2022-04-19 | 2Seventy Bio Inc | Flerdelte signaleringsproteiner og anvendelser deraf |
US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
CN111849912B (zh) | 2014-02-14 | 2024-03-15 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
US20170175128A1 (en) | 2014-04-18 | 2017-06-22 | Editas Medicine, Inc. | Crispr-cas-related methods, compositions and components for cancer immunotherapy |
CA2984484C (fr) | 2014-05-02 | 2024-01-23 | The Trustees Of The University Of Pennsylvania | Compositions de recepteurs d'auto-anticorps chimeriques et procedes afferents |
RU2691102C2 (ru) | 2014-05-08 | 2019-06-11 | Сангамо Байосайенсиз, Инк. | Способы и композиции для лечения болезни хантингтона |
MX2016015383A (es) | 2014-05-29 | 2017-02-28 | Us Health | Receptores de celulas t anti - papilomavirus 16 e7 humano. |
WO2016014794A1 (fr) | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Procédés et compositions pour moduler l'ingénierie génomique médiée par les nucléases dans des cellules souches hématopoïétiques |
US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
PL3177640T3 (pl) | 2014-08-08 | 2020-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Charakteryzujące się wysokim powinowactwem środki terapeutyczne naśladujące PD-11 i sposoby ich wykorzystania |
EP2990416B1 (fr) | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Récepteur d'antigène chimérique universel exprimant des cellules immunitaires pour le ciblage de divers antigènes multiples et son procédé de fabrication et son utilisation pour le traitement du cancer, des infections et des troubles auto-immuns |
WO2016090312A1 (fr) | 2014-12-05 | 2016-06-09 | Memorial Sloan-Kettering Cancer Center | Récepteurs d'antigènes chimériques ciblant un récepteur couplé à la protéine g et leurs utilisations |
EP3872094A3 (fr) | 2014-12-05 | 2021-12-08 | Memorial Sloan Kettering Cancer Center | Anticorps ciblant un antigène de maturation des lymphocytes b et procédés d'utilisation |
CN113429482A (zh) | 2014-12-05 | 2021-09-24 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的抗体和使用方法 |
AU2015357526B2 (en) | 2014-12-05 | 2022-03-17 | Eureka Therapeutics, Inc. | Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof |
CA2991301A1 (fr) | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Procedes d'administration et compositions pour genie genomique medie par nuclease |
MX2018006767A (es) | 2015-12-04 | 2019-03-14 | Novartis Ag | Composiciones y metodos para oncologia inmunologica. |
JP7128741B2 (ja) | 2015-12-18 | 2022-08-31 | サンガモ セラピューティクス, インコーポレイテッド | T細胞受容体の標的化破壊 |
AU2017261380A1 (en) | 2016-05-06 | 2018-11-22 | Editas Medicine, Inc. | Genetically engineered cells and methods of making the same |
JP7060591B2 (ja) * | 2016-10-17 | 2022-04-26 | 2セブンティ バイオ インコーポレイテッド | TGFβR2エンドヌクレアーゼバリアント、組成物、および使用方法 |
CA3081456A1 (fr) * | 2017-11-01 | 2019-05-09 | Editas Medicine, Inc. | Procedes, compositions et composants pour l'edition crispr-cas9 de tgfbr2 dans des cellules t pour l'immunotherapie |
EA202191463A1 (ru) * | 2018-11-28 | 2021-10-13 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде |
-
2020
- 2020-04-30 CA CA3136737A patent/CA3136737A1/fr active Pending
- 2020-04-30 MA MA055811A patent/MA55811A/fr unknown
- 2020-04-30 CN CN202080047290.9A patent/CN114025788A/zh active Pending
- 2020-04-30 US US17/607,816 patent/US20220184131A1/en active Pending
- 2020-04-30 JP JP2021564439A patent/JP2022531222A/ja active Pending
- 2020-04-30 AU AU2020265741A patent/AU2020265741A1/en active Pending
- 2020-04-30 SG SG11202111360YA patent/SG11202111360YA/en unknown
- 2020-04-30 WO PCT/US2020/030815 patent/WO2020223535A1/fr unknown
- 2020-04-30 KR KR1020217039324A patent/KR20220016475A/ko unknown
- 2020-04-30 EP EP20729274.9A patent/EP3962520A1/fr active Pending
- 2020-04-30 BR BR112021021075A patent/BR112021021075A2/pt unknown
- 2020-04-30 MX MX2021013219A patent/MX2021013219A/es unknown
-
2021
- 2021-10-12 IL IL287207A patent/IL287207A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021021075A2 (pt) | 2021-12-14 |
WO2020223535A1 (fr) | 2020-11-05 |
AU2020265741A1 (en) | 2021-11-25 |
CA3136737A1 (fr) | 2020-11-05 |
EP3962520A1 (fr) | 2022-03-09 |
JP2022531222A (ja) | 2022-07-06 |
IL287207A (en) | 2021-12-01 |
SG11202111360YA (en) | 2021-11-29 |
US20220184131A1 (en) | 2022-06-16 |
KR20220016475A (ko) | 2022-02-09 |
CN114025788A (zh) | 2022-02-08 |
MX2021013219A (es) | 2022-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA55811A (fr) | Cellules exprimant un récepteur recombinant à base d'un locus modifié du tgfbr2, et polynucléotides et méthodes associés | |
EA202191463A1 (ru) | Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде | |
AU2019204735A1 (en) | Field-programmable gate array based trusted execution environment for use in a blockchain network | |
MA55069A (fr) | Nouvelles protéines de fusion spécifique à cd137 et gpc3 | |
MA52207A (fr) | Lymphocytes t exprimant un récepteur recombinant, polynucléotides et procédés associés | |
DK3811748T3 (da) | Lugemaskine og fremgangsmåde til udførelse af lugning under anvendelse af lugemaskinen | |
EP3804741A3 (fr) | Procédé de sélection de lymphocytes t génétiquement modifiés | |
MA50201A (fr) | Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants | |
DK3790548T3 (da) | Fremgangsmåder til forbedring af biotilgængeligheden og eksponeringen af en åbner af spændingsstyret kaliumkanal | |
UA42369S (uk) | Комп'ютер | |
IL285454A (en) | Flexible construction unit, kit and method for building a structure | |
EP3963890A4 (fr) | Établissement d'une liste de candidats de mouvement à l'aide d'informations de bloc voisin | |
SG11202111372VA (en) | Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods | |
DK3629273T3 (da) | Apparat, computerprogram og fremgangsmåde | |
MA51790A (fr) | Échafaudages issus du génie tissulaire, bioréacteurs instrumentés et procédés d'utilisation associés | |
DE602004001058D1 (de) | Hörhilfegerät mit einer Zoom-Funktion für das Ohr eines Individuums | |
UA145741U (uk) | Спосіб створення захисного зображення | |
Romeu et al. | Recommendations for online teamwork | |
FR2878987B1 (fr) | Interface haptique a cables | |
林汉钊 | A case study of Conversation Analysis based on Labov's Narrative Structure Theory | |
UA40125S (uk) | Молоток покрівельника | |
PL429914A1 (pl) | Mobilna rozstawna osłona separująco-ochronna | |
JP1729372S (ja) | 充電パイル | |
JP1754197S (ja) | 帽子 | |
MA45634B1 (fr) | Boulier à plusieurs compartiments |